Company profile: Acousia Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule therapeutics for sensorineural hearing loss, with expertise in identifying and developing drug candidates to enhance and preserve natural hearing. Products include ACOU085, an etiology-agnostic otoprotective candidate preventing chemotherapy-induced hearing loss and sensory hair cell death, and ACOU082, an oral Kv7.4 activator to enhance natural hearing and protect against age-related loss.
Products and services
- Small molecule therapeutics for SNHL: Development of small molecule drug candidates with a dual mode of action targeting sensorineural hearing loss (SNHL) to enhance and preserve natural hearing
- ACOU082: A proprietary small-molecule Kv7.4 activator developed for oral administration, aimed at enhancing natural hearing and preserving hearing capacity, particularly against age-related hearing loss
- ACOU085: An etiology-agnostic small-molecule otoprotective candidate engineered to prevent chemotherapy-induced hearing loss and reduce sensory hair cell death specifically in cancer patients undergoing treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acousia Therapeutics
Creative Medical Technology
HQ: United States
Website
- Description: Provider of regenerative and cell therapy platforms in immunology, urology, neurology, and orthopedics, including ImmCelzTM autologous immune cell therapy; Enhanced Allogenic Platform using perinatal tissue cells; Supercharged Autologous Immunotherapy; Reprogrammed Cell Therapy with iPSCs; Rapid Autologous Therapies, and CaverStem for erectile dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Creative Medical Technology company profile →
OvaScience
HQ: United States
Website
- Description: Provider of life sciences solutions focused on the discovery, development and commercialization of treatments for infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OvaScience company profile →
Imel Biotherapeutics
HQ: United States
Website
- Description: Provider of cell-based therapies for mitochondrial disorders, including autologous mitochondria-replaced T cells (Mir T Cells) and mitochondrial enhancement therapies that replace dysfunctional mitochondria with healthy ones to restore cellular functionality, reprogram T cells, and overcome T cell exhaustion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imel Biotherapeutics company profile →
Cytori
HQ: United States
Website
- Description: Provider of autologous cell therapies and medical technologies, including the Celution System to automate and standardize extraction and concentration of adult adipose-derived regenerative cells (ADRCs) in clinical settings; StemSource Cell Bank for cryopreserving and recovering viable ADRCs; Celase GMP enzyme for dissociating nucleated cells from adipose tissue; Celbrush surgical instrument for precise delivery of micro droplets of tissue; and an Early Access Program for systemic scleroderma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytori company profile →
Neurona Therapeutics
HQ: United States
Website
- Description: Provider of cell therapies for neurological disorders, including NRTX-1001, a one-time dose therapy for drug-resistant focal epilepsy using human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells; myelinating glial cell therapy using human oligodendrocytes to restore myelin; and gene-edited neural cell therapies for targeted delivery to the CNS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurona Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acousia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acousia Therapeutics
2.2 - Growth funds investing in similar companies to Acousia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acousia Therapeutics
4.2 - Public trading comparable groups for Acousia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →